
Takeda Pharmaceutical Company Limited: updates and filings
Price
$21.93
November 20, 2026
What Ploutos Investor adds for Takeda Pharmaceutical
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from FY2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Oct 29, 2026Current report (foreign company)Form6-K
- Oct 29, 2026Current report (foreign company)Form6-K
- Sep 14, 2026Current report (foreign company)Form6-K
- Aug 31, 2026Current report (foreign company)Form6-K
- Aug 6, 2026Current report (foreign company)Form6-K
- Jul 30, 2026Current report (foreign company)Form6-K
- Jul 9, 2026Current report (foreign company)Form6-K
- Jul 8, 2026Current report (foreign company)Form6-K
- Jun 29, 2026Current report (foreign company)Form6-K
- Jun 26, 2026Current report (foreign company)Form6-K
- Jun 24, 2026Current report (foreign company)Form6-K
- Jun 24, 2026Current report (foreign company)Form6-K
- Jun 24, 2026Current report (foreign company)Form6-K
- Jun 17, 2026FilingFormIRANNOTICE
- Jun 17, 2026Annual report (foreign company)for the period to Mar 31, 2026Form20-F
- Jun 9, 2026Current report (foreign company)Form6-K
- Jun 5, 2026Current report (foreign company)Form6-K
- Jun 5, 2026Current report (foreign company)Form6-K
- Jun 1, 2026Current report (foreign company)Form6-K
- May 26, 2026Current report (foreign company)Form6-K
- May 26, 2026Current report (foreign company)Form6-K
- May 26, 2026Current report (foreign company)Form6-K
- May 26, 2026Current report (foreign company)Form6-K
- May 26, 2026Current report (foreign company)Form6-K
- May 22, 2026Conflict minerals reportFormSD
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Oct 29, 2026 | 6-K | Current report (foreign company) | Document |
| Oct 29, 2026 | 6-K | Current report (foreign company) | Document |
| Sep 14, 2026 | 6-K | Current report (foreign company) | Document |
| Aug 31, 2026 | 6-K | Current report (foreign company) | Document |
| Aug 6, 2026 | 6-K | Current report (foreign company) | Document |
| Jul 30, 2026 | 6-K | Current report (foreign company) | Document |
| Jul 9, 2026 | 6-K | Current report (foreign company) | Document |
| Jul 8, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 29, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 26, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 24, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 24, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 24, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 17, 2026 | IRANNOTICE | Filing | Document |
| Jun 17, 2026 | 20-F | Annual report (foreign company)for the period to Mar 31, 2026 | Document |
| Jun 9, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 5, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 5, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 1, 2026 | 6-K | Current report (foreign company) | Document |
| May 26, 2026 | 6-K | Current report (foreign company) | Document |
| May 26, 2026 | 6-K | Current report (foreign company) | Document |
| May 26, 2026 | 6-K | Current report (foreign company) | Document |
| May 26, 2026 | 6-K | Current report (foreign company) | Document |
| May 26, 2026 | 6-K | Current report (foreign company) | Document |
| May 22, 2026 | SD | Conflict minerals report | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 5, 2007.
The full analysis
What do Takeda Pharmaceutical's filings show?
The filings are where every one of Takeda Pharmaceutical's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.